National Pension Service Sells 11,992 Shares of IQVIA Holdings Inc. $IQV

National Pension Service decreased its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 4.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 275,097 shares of the medical research company’s stock after selling 11,992 shares during the quarter. National Pension Service owned 0.16% of IQVIA worth $62,010,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in the company. Rothschild Investment LLC grew its holdings in shares of IQVIA by 106.8% during the fourth quarter. Rothschild Investment LLC now owns 910 shares of the medical research company’s stock valued at $205,000 after buying an additional 470 shares during the last quarter. SBI Okasan Asset Management Co.Ltd. purchased a new stake in shares of IQVIA during the fourth quarter valued at approximately $2,839,000. Northwestern Mutual Wealth Management Co. grew its holdings in shares of IQVIA by 3.2% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 259,800 shares of the medical research company’s stock valued at $58,561,000 after buying an additional 8,072 shares during the last quarter. Baker Avenue Asset Management LP purchased a new stake in shares of IQVIA during the fourth quarter valued at approximately $213,000. Finally, Huntington National Bank grew its holdings in shares of IQVIA by 28.3% during the fourth quarter. Huntington National Bank now owns 1,243 shares of the medical research company’s stock valued at $280,000 after buying an additional 274 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Trading Up 0.5%

Shares of IQV stock opened at $182.03 on Friday. IQVIA Holdings Inc. has a 12-month low of $136.41 and a 12-month high of $247.04. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20. The firm’s 50 day moving average is $170.34 and its 200 day moving average is $196.18. The stock has a market capitalization of $30.38 billion, a P/E ratio of 22.56, a P/E/G ratio of 1.74 and a beta of 1.18.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The business had revenue of $4.15 billion for the quarter, compared to the consensus estimate of $4.10 billion. During the same period last year, the firm earned $2.70 earnings per share. The company’s quarterly revenue was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Research analysts expect that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA declared that its board has authorized a stock buyback program on Thursday, May 7th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s management believes its shares are undervalued.

Analyst Ratings Changes

A number of equities research analysts have recently commented on IQV shares. BMO Capital Markets set a $250.00 price target on shares of IQVIA in a report on Friday, February 6th. Morgan Stanley set a $225.00 price target on shares of IQVIA in a report on Thursday, May 7th. Weiss Ratings downgraded shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, May 4th. Citigroup dropped their target price on shares of IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a report on Friday, February 6th. Finally, JPMorgan Chase & Co. dropped their target price on shares of IQVIA from $255.00 to $225.00 and set an “overweight” rating on the stock in a report on Friday, February 6th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $225.69.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.